ARTICLE | Clinical News
Cell Pathways completes enrollment
March 29, 2000 8:00 AM UTC
CLPA completed enrollment in an open-label 1-year Phase II trial of Aptosyn exisulind, a selective apoptosis inducer, to treat children with familial adenomatous polyposis. ...